Anvirzel Leaflet A4

ANVIRZEL
tm
R.G.C.C. Pharma Ltd
5th floor, Broad Quay House
Prince street
Bristol, BS1 4DJ
United Kingdom
Tel: 0044 (0)1179058738, 0044 (0) 1172305034
Fax: 0044 (0) 1179058800, 0044 (0) 1173701077
E-mail: info@rgcc-pharma.com
Local Supplier for the area of:
"A nat�ral defence and
suppor� against cancer and
enhancer of recommended therapies for malig�ancies."
R.G.C.C. Pharma Ltd
Direct anticancer effect
Anvirzel™ is an extract of Nerium oleander, a shrub or tree of
Apocynaceae family. It is a compound that mainly consists of polysacchrides, proteins and two cardiac glycosides, Oleandrin and
Oleandrigenin. The above glycosides have been used for many
decades in treatment of heart failure and it has been proved that are
able to inhibit prolieration of tumor cells. According to literature
data, Anvirzel™ reduces the cancer cells in pancreatic and prostate
cancer. Recently laboratory experimental data have also proven that
Anvirzel™ has a wider field of action, also in other cancer types,
such as breast, lung and colon cancer. It has been also proved that
Anvirzel™ is more effective in low concentrations, thus avoiding the
toxicity due to high concentrations of the drug.
Enhancing the effect of chemotherapy – reducing
side effects
There have been also performed experiments testing the efficacy of
Anvirzel™ with other established chemotherapy drugs, such as
Cisplatin, Carboplatin and Docetaxel. These drugs have high toxicity
and side effects, when used in higher concentrations, which however
are more effective. It has been proved that the combination with
Anvirzel™ is more effective than monotherapy and the most important is that the combination has better efficacy at low concentrations,
thus preventing the toxicity of chemotherapy.
Clinical Studies
Anvirzel has completed a variety of pilot studies in human as well as
phase I of clinical trials at the Cleveland Clinic. In addition, a new
FDA IND # 111484 has been approved for the initiation of a clinical
trial of Anvirzel Sublingual at MD Anderson Cancer Center in nonsmall cell lung cancer.
Conclusion
In conclusion, Anvirzel™ is an extract, with demonstrated anticancer
properties in many types of cancer in human. By using it in combination with established chemotherapeutics, it is requires a lower concentration of them, reducing the side effects of therapy at the same time
achieving much better results.
Anvirzel formulations are for intramuscular (IM)
and sublingual use.
Synergistic effect
1 5 0 ,0 0 0
Reduction percentage in Lung
cancer
Reduction percentage in
Prostate Cancer
0 .0 1 n g/ml An virzel™
100,000
1 0 0 ,0 0 0
0 ,0 1 ng/ml
Anvirzel™
0 .1 u g/ml Carb op latin
5 0 ,0 0 0
0 .1 u g/ml Docetaxel
0 ,0 0 0
48h
- 5 0 ,0 0 0
72h
Carb op latin + 0 .1 u g/ml
Docetaxel
0 .0 1 n g/ml An virzel™
+ 0 .1 u g/ml
0,1 μg/ml
Cisplatin
50,000
0,000
0,01 ng/ml
Anvirzel™ + 0 ,1
μg/ml Cisplatin
48h
72h
References:
1. Apostolou P, Toloudi M, Chatziioannou M, Papasotiriou I: Determination of efficacy of
AnvirzelTM in 37 established cancer cell lines. International Pharmaceutical Industry
2011;3(3):68-72.
2. Pathak S, Multani AS, Narayan S, Kumar V, Newman RA: Anvirzel, an extract of
Nerium oleander, induces cell death in human but not murine cancer cells. Anticancer
Drugs 2000;11(6):455-63.
3. Smith JA, Madden T, Vijjeswarapu M, Newman RA. Inhibition of export of fibroblast
growth factor-2 (FGF-2) from the prostate cancer cell lines PC3 and DU145 by Anvirzel
and its cardiac glycoside component, oleandrin. Biochem Pharmacol 2001;62:469-72.